Process for the Preparation of Pyridin-2-Ylmethylsulphinyl-1H-Benzimidazol Compounds
The invention relates to a novel process for preparing mixtures of enantiomers of PPI's having a sulphinyl structure using a mixture of enantiomers of chiral zirconium complexes or chiral hafnium complexes.
1 . A process for preparing a mixture of enantiomers of a PPI having a sulphinyl structure comprising oxidizing a corresponding sulphide in the presence of a mixture of enantiomers of chiral zirconium complexes or chiral hafnium complexes.
2 . A process for preparing a mixture of enantiomers of a PPI having a sulphinyl structure comprising oxidizing a corresponding sulphide in the presence of a mixture of enantiomers of chiral zirconium complexes.
3 . The process according to claim 1 , characterized in that the oxidation is carried out using cumene hydroperoxide.
4 . The process according to claim 1 , characterized in that zirconium(IV) acetylacetonate, zirconium(IV) butoxide, zirconium(IV) tert-butoxide, zirconium(IV) ethoxide, zirconium(IV) n-propoxide, zirconium(IV) isopropoxide or zirconium(IV) isopropoxide/isopropanol complex or hafnium(IV) acetylacetonate, hafnium(IV) butoxide, hafnium(IV) tert-butoxide, hafnium(IV) ethoxide, hafnium(IV) n-propoxide, hafnium(IV) isopropoxide or hafnium(IV) isopropoxide/isopropanol complex is used.
5 . The process according to claim 2 , characterized in that zirconium(IV) acetylacetonate, zirconium(IV) butoxide, zirconium(IV) tert-butoxide, zirconium(IV) ethoxide, zirconium(IV) n-propoxide, zirconium(IV) isopropoxide or zirconium(IV) isopropoxide/isopropanol complex is used.
6 . The process according to claim 1 , characterized in that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid derivatives.
7 . The process according to claim 1 , characterized in that the process is carried out in the presence of a racemic mixture of D/L-tartaric acid derivatives.
8 . The process according to claim 1 , characterized in that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid bis-(N,N-diallylamide), D/L-tartaric acid bis-(N,N-dibenzylamide), D/L-tartaric acid bis-(N,N-diisopropylamide), D/L-tartaric acid bis-(N,N-dimethylamide), D/L-tartaric acid bis-(N-pyrrolidinamide, D/L-tartaric acid bis-(N-piperidinamide), D/L-tartaric acid bis-(N-morpholinamide), D/L-tartaric acid bis-(N-cycloheptylamide), D/L-tartaric acid bis-(N-4-methyl-N-piperazinamide), dibutyl D/L-tartrate, di-tert-butyl D/L-tartrate, diisopropyl D/L-tartrate, dimethyl D/L-tartrate or diethyl D/L-tartrate.
9 . The process according to claim 1 , characterized in that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid bis-(N,N-dimethylamide), D/L-tartaric acid bis-(N-pyrrolidinamide) or D/L-tartaric acid bis-(N-morpholinamide).
10 . The process according to claim 1 , characterized in that the oxidation is carried out in the presence of an organic base.
11 . The process according to claim 1 , characterized in that the oxidation is carried out in the presence of a tertiary amine.
12 . The process according to claim 1 , characterized in that the oxidation is carried out in organic solvents.
13 . The process according to claim 1 , characterized in that the oxidation is carried out in organic solvents comprising 0 to 0.3% by volume of water.
14 . The process according to claim 1 , characterized in that the oxidation is carried out in an organic solvent which comprises methyl isobutyl ketone.
15 . The process according to claim 1 , characterized in that the zirconium component used is zirconium(IV) acetylacetonate, zirconium(IV) butoxide, zirconium(IV) tert-butoxide, zirconium(IV) ethoxide, zirconium(IV) n-propoxide, zirconium(IV) isopropoxide, or zirconium(IV) isopropoxide/isopropanol complex, and that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid bis-(N,N-diallylamide), D/L-tartaric acid bis-(N,N-dibenzylamide), D/L-tartaric acid bis-(N,N-diisopropylamide), D/L-tartaric acid bis-(N,N-dimethylamide), D/L-tartaric acid bis-(N-pyrrolidinamide), D/L-tartaric acid bis-(N-piperidinamide), D/L-tartaric acid bis-(N-morpholinamide), D/L-tartaric acid bis-(N-cycloheptylamide), D/L-tartaric acid bis-(N-4-methyl-N-piperazinamide), dibutyl D/L-tartrate, di-tert-butyl D/L-tartrate, diisopropyl D/L-tartrate, dimethyl D/L-tartrate or diethyl D/L-tartrate.
16 . The process according to claim 1 , characterized in that the zirconium component used is zirconium(IV) acetylacetonate, zirconium(IV) butoxide, zirconium(IV) tert-butoxide, zirconium(IV) ethoxide, zirconium(IV) n-propoxide, zirconium(IV) isopropoxide, or zirconium(IV) isopropoxide/isopropanol complex and that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid bis-(N,N-diallylamide), D/L-tartaric acid bis-(N,N-dibenzylamide), D/L-tartaric acid bis-(N,N-diisopropylamide), D/L-tartaric acid bis-(N,N-dimethylamide), D/L-tartaric acid bis-(N-pyrrolidinamide), D/L-tartaric acid bis-(N-piperidinamide), D/L-tartaric acid bis-(N-morpholinamide), D/L-tartaric acid bis-(N-cycloheptylamide), D/L-tartaric acid bis-(N-4-methyl-N-piperazinamide), dibutyl D/L-tartrate, di-tert-butyl D/L-tartrate, diisopropyl D/L-tartrate, dimethyl D/L-tartrate or diethyl D/L-tartrate and in the presence of an organic base.
17 . The process according to claim 1 , characterized in that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid bis-(N,N-dimethylamide), D/L-tartaric acid bis-(N-pyrrolidinamide) or D/L-tartaric acid bis-(N-morpholinamide) and in the presence of an organic base.
18 . The process according to claim 1 , characterized in that a mixture of enantiomers of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1H-benzimidazole, 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methyl-sulphinyl]-1H-benzimidazole, 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulphinyl]-1H-benzimidazole, 2-{[4-[3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulphinyl}-1H-benzimidazole or 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridylmethyl)sulphinyl/}-1H-imidazo(4,5-b)pyridine is prepared by the process.
19 . The process according to claim 1 , characterized in that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid bis-(N,N-dimethylamide), D/L-tartaric acid bis-(N-pyrrolidinamide) or D/L-tartaric acid bis-(N-morpholinamide) and that the process product prepared is of a mixture of enantiomers of pantoprazole.
20 . The process according to claim 1 , characterized in that the zirconium component used is zirconium(IV) n-propoxide, zirconium(IV) isopropoxide or zirconium(IV) isopropoxide/isopropanol complex, that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid bis-(N,N-dimethylamide), D/L-tartaric acid bis-(N-pyrrolidinamide) or D/L-tartaric acid bis-(N-morpholinamide) that the oxidation is carried out using cumene hydroperoxide and that the process product prepared is a mixture of enantiomers of pantoprazole.
21 . The process according to claim 1 , characterized in that the zirconium component used is zirconium(IV) n-propoxide, zirconium(IV) isopropoxide or zirconium(IV) isopropoxide/isopropanol complex, that the process is carried out in the presence of a mixture of enantiomers of D/L-tartaric acid bis-(N,N-dimethylamide), D/L-tartaric acid bis-(N-pyrrolidinamide) or D/L-tartaric acid bis-(N-morpholinamide) that the oxidation is carried out using cumene hydroperoxide in the presence of a tertiary amine and that the process product prepared is pantoprazole.
22 . The process according to claim 1 , characterized in that the zirconium component used is zirconium(IV) n-propoxide or zirconium(IV) isopropoxide complex, that the process is carried out in the presence of a racemic mixture of enantiomers of D/L-tartaric acid bis-(N-pyrrolidinamide), that the oxidation is carried out using cumene hydroperoxide in the presence of a tertiary amine and that the process product prepared is a racemic mixture of enantiomers of pantoprazole.
23 . A mixture of enantiomers of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1H-benzimidazole, 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1H-benzimidazole, 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulphinyl]-1H-benzimidazole, 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulphinyl}-1H-benzimidazole or 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridylmethyl)sulphinyl)-1H-imidazo[4,5-b]pyridine prepared by the process according to claim 1.